Stay updated on SL-401 in BPDCN or AML Clinical Trial
Sign up to get notified when there's something new on the SL-401 in BPDCN or AML Clinical Trial page.

Latest updates to the SL-401 in BPDCN or AML Clinical Trial page
- Check4 days agoChange DetectedNew publication added to Publications: Konopleva M, Pemmaraju N, Sweet KL, Stein AS, Rizzieri DA, Wang ES, Vasu S, Rosenblat T, Zuurman M, Gupta I, Lane AA. Hematopoietic effects of tagraxofusp in treatment-naive patients with blastic plasmacytoid dendritic cell neoplasm. Cancer. 2026 Jan 1;132(1):e70243.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedAdded a Locations section listing participating states (California, Florida, Massachusetts, New York, North Carolina, Ohio, Pennsylvania, Texas) and updated the page revision to v3.3.3. Removed the HHS Vulnerability Disclosure link.SummaryDifference0.9%

- Check26 days agoNo Change Detected
- Check47 days agoChange DetectedAdded a note that publications are automatically filled from PubMed and updated the page revision to v3.3.2. The older PubMed data source description was removed.SummaryDifference0.1%

- Check54 days agoChange DetectedThe general government operating-status notice on the page was removed. Trial details, inclusion criteria, and listed locations remain unchanged.SummaryDifference0.3%

- Check69 days agoChange DetectedResults data and related publications have been added to the study record, including primary and secondary outcomes and survival metrics. Study record dates have been updated to reflect results submission.SummaryDifference0.4%

- Check97 days agoChange DetectedUpdate to version v3.2.0 and an operating-status notice; removal of a specific medical term and the older version label (v3.1.0).SummaryDifference3%

Stay in the know with updates to SL-401 in BPDCN or AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SL-401 in BPDCN or AML Clinical Trial page.